FTC crackdown on deceptive CBD product ads

The Federal Trade Commission has announced the first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The FTC is taking action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others.

The FTC is requiring each of the companies, and individuals behind them, to stop making such unsupported health claims immediately, and several will pay monetary judgments to the agency. The orders settling the FTC’s complaints also bar the respondents from similar deceptive advertising in the future, and require that they have scientific evidence to support any health claims they make for CBD and other products.

The targeted companies include Bionatrol Health,LLC; Isle Reveine, LLC; EpicHouse LLC; CBD Meds, Inc.; HempMeCBD; Reef Industries, Inc.; and Steves Distributing, LLC